Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine - Innocoll

Drug Profile

Bupivacaine - Innocoll

Alternative Names: B-Implant; Bupivacaine HCl collagen-matrix implants - Innocoll; Bupivacaine hydrochloride; Bupivacaine hydrochloride implant - Innocoll; Bupivacaine implant - Innocoll; Bupivacaine-collagen bioresorbable implant - Innocoll; CollaRx® Bupivacaine implant; INL-001; INN-LD-01; XaraColl

Latest Information Update: 24 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innocoll
  • Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative pain
  • Discontinued Pain

Most Recent Events

  • 24 Feb 2023 Discontinued for Pain in USA (unspecified route)
  • 10 Jan 2023 Innocoll completes a phase III trial in Postoperative pain (In adults, In the elderly) in USA (Implant) (NCT04785638)
  • 02 Mar 2022 Innocoll announces intention to submit sNDA to the US FDA for postoperative pain
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top